Natera Inc (NASDAQ:NTRA) COO Steven Leonard Chapman sold 3,410 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $16.00, for a total value of $54,560.00. Following the transaction, the chief operating officer now owns 10,299 shares of the company’s stock, valued at approximately $164,784. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, December 24th, Steven Leonard Chapman sold 565 shares of Natera stock. The stock was sold at an average price of $12.39, for a total value of $7,000.35.
NASDAQ NTRA traded up $0.08 during trading on Friday, hitting $19.00. The stock had a trading volume of 15,083 shares, compared to its average volume of 610,960. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.44 and a quick ratio of 2.32. The company has a market cap of $1.03 billion, a P/E ratio of -8.83 and a beta of 1.84. Natera Inc has a one year low of $8.60 and a one year high of $29.62.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can lifted its stake in Natera by 136.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after purchasing an additional 3,420 shares during the last quarter. Legal & General Group Plc lifted its stake in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Natera during the third quarter valued at approximately $106,000. Point72 Hong Kong Ltd bought a new stake in shares of Natera during the third quarter valued at approximately $119,000. Finally, Quantbot Technologies LP bought a new stake in shares of Natera during the third quarter valued at approximately $135,000. 90.05% of the stock is owned by institutional investors and hedge funds.
Several research analysts recently commented on the company. BidaskClub lowered Natera from a “sell” rating to a “strong sell” rating in a research report on Friday, March 1st. Zacks Investment Research upgraded Natera from a “sell” rating to a “hold” rating in a research report on Friday. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price target on shares of Natera in a research report on Monday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Natera currently has a consensus rating of “Buy” and a consensus price target of $27.75.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Week Herald and is the property of of Week Herald. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://weekherald.com/2019/03/15/natera-inc-ntra-coo-sells-54560-00-in-stock.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: Options Trading
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.